Heron Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Heron Therapeutics

03/11/2023 12:48

* Heron Therapeutics Inc  HRTX.OQ   HRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The San Diego California-based  company is expected to
report  a
22.9% increase in revenue to $32.65 million from $26.56 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Heron Therapeutics
Inc is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $7​, above​ its last closing price of $0.66.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.23       -0.23      -0.35     Missed  -50
 Mar. 31 2023  -0.21       -0.20      -0.27     Missed  -33
 Dec. 31 2022  -0.30       -0.28      -0.17     Beat    40.4​
 Sep. 30 2022  -0.38       -0.38      -0.38     Met     -1.1
 ​​Jun.        -0.53       -0.50      -0.55     Missed  -8.9
 30 2022                                                
 Mar. 31 2022  -0.49       -0.48      -0.63     Missed  -32.4​
 Dec. 31 2021  -0.58       -0.58      -0.54     Beat    6.3
 Sep. 30 2021  -0.61       -0.61      -0.51     Beat    16.1
 This summary was machine generated November 3 at 12:47 GMT.  All
figures in US dollars  unless otherwise stated